Home Cart Sign in  
Chemical Structure| 52068-30-1 Chemical Structure| 52068-30-1

Structure of 52068-30-1

Chemical Structure| 52068-30-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Valeria Lallai ; A.C. Martin ; J.P. Fowler ; Malia Bautista ; Allison S. Mogul ; Jinjutha E. Cheepluesak , et al.

Abstract: The opioid epidemic has led to a devastating loss of life nationwide. Of those dependent on opioids, many individuals desire to quit or reduce use, but their efforts are often unsuccessful given the powerful reinforcing properties associated with opioid drugs, especially fentanyl given its high potency and speed of onset. Here, we developed a novel theraputic based on a newly developed artificial intelligence (AI)-based platform, which was rationally designed to identify markers of dysregulation from human drug user postmortem brain tissue. The GATC-021 compound was synthesized and validated with in vitro screening for target specificity. Thereafter, GATC-021 was examined for its effectiveness in modulating opioid dependence with an animal model of addiction. We found that GATC-021 substantially reduced fentanyl intake in both male and female rats, as assessed with intravenous self-administration. However, given drug soluability challenges, additional studies are needed to better develop drug formulations to permit translation into clinical populations more effectively. Taken together, these findings validate our AI-based platform for novel therapeutic development with a polypharmacy approach and further support the effectiveness of such target modulation as a promising therapeutic approach for those suffering from opioid use disorder.

Keywords: Opioid ; Addiction ; Fentanyl ; Therapeutic Development

Purchased from AmBeed: ;

Alternative Products

Product Details of [ 52068-30-1 ]

CAS No. :52068-30-1
Formula : C13H15ClN2O
M.W : 250.72
SMILES Code : NNC1=CC=C(OCC2=CC=CC=C2)C=C1.[H]Cl
MDL No. :MFCD00137741
InChI Key :OVNUPJXMCMTQCN-UHFFFAOYSA-N
Pubchem ID :3016725

Safety of [ 52068-30-1 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Computational Chemistry of [ 52068-30-1 ] Show Less

Physicochemical Properties

Num. heavy atoms 17
Num. arom. heavy atoms 12
Fraction Csp3 0.08
Num. rotatable bonds 4
Num. H-bond acceptors 2.0
Num. H-bond donors 2.0
Molar Refractivity 71.59
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

47.28 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.0
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

3.83
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

3.01
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

2.88
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.87
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.32

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-4.07
Solubility 0.0216 mg/ml ; 0.000086 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-4.52
Solubility 0.0076 mg/ml ; 0.0000303 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-4.76
Solubility 0.00437 mg/ml ; 0.0000174 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

Yes
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.11 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.81

Application In Synthesis of [ 52068-30-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 52068-30-1 ]

[ 52068-30-1 ] Synthesis Path-Downstream   1~1

  • 1
  • [ 5400-79-3 ]
  • [ 52068-30-1 ]
  • [ 159188-73-5 ]
YieldReaction ConditionsOperation in experiment
With acetic acid; In water; ethyl acetate; EXAMPLE 5 1,2,3,4-Tetrahydro-7-phenylmethoxycyclopent[b]indole-2-carboxylic acid ethyl ester To 250 ml of 80% acetic acid in water, were added 4-phenylmethoxyphenylhydrazine hydrochloride (30 g, 0.12 mole) and 3-oxocyclopentane carboxylic acid ethyl ester (20 g, 0.13 mole). After stirring at ambient temperature for one hour and then at 100 C. for four hours, the mixture was cooled and poured into one liter of water. After stirring for five minutes, the mixture was extracted with ethyl acetate (3*). The organic layer was washed successively with water (2*) and saturated sodium chloride solution, and thereafter dried over anhydrous MgSO4. After filtering, the solution was concentrated to a dark oil (~48 g), which was eluted on a silica gel column with 5% ethyl acetate/dichloromethane via HPLC. The desired fractions were combined and concentrated to give the product as a thick brown oil (24.1 g). Analysis: Calculated for C21 H21 NO3: 75.20%C 6.31%H 4.18%N Found: 74.94%C 6.22%H 4.13%N
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 52068-30-1 ]

Aryls

Chemical Structure| 51388-20-6

A118850 [51388-20-6]

4-(Benzyloxy)aniline hydrochloride

Similarity: 0.90

Chemical Structure| 6373-46-2

A203826 [6373-46-2]

4-(Benzyloxy)aniline

Similarity: 0.88

Chemical Structure| 1484-26-0

A113442 [1484-26-0]

3-Benzyloxyaniline

Similarity: 0.86

Chemical Structure| 1159825-08-7

A189900 [1159825-08-7]

4-(Benzyloxy)-3-methoxyaniline hydrochloride

Similarity: 0.85

Chemical Structure| 60481-02-9

A188510 [60481-02-9]

(4-Phenoxyphenyl)hydrazine hydrochloride

Similarity: 0.82

Ethers

Chemical Structure| 51388-20-6

A118850 [51388-20-6]

4-(Benzyloxy)aniline hydrochloride

Similarity: 0.90

Chemical Structure| 6373-46-2

A203826 [6373-46-2]

4-(Benzyloxy)aniline

Similarity: 0.88

Chemical Structure| 1484-26-0

A113442 [1484-26-0]

3-Benzyloxyaniline

Similarity: 0.86

Chemical Structure| 1159825-08-7

A189900 [1159825-08-7]

4-(Benzyloxy)-3-methoxyaniline hydrochloride

Similarity: 0.85

Chemical Structure| 60481-02-9

A188510 [60481-02-9]

(4-Phenoxyphenyl)hydrazine hydrochloride

Similarity: 0.82

Amines

Chemical Structure| 51388-20-6

A118850 [51388-20-6]

4-(Benzyloxy)aniline hydrochloride

Similarity: 0.90

Chemical Structure| 6373-46-2

A203826 [6373-46-2]

4-(Benzyloxy)aniline

Similarity: 0.88

Chemical Structure| 1484-26-0

A113442 [1484-26-0]

3-Benzyloxyaniline

Similarity: 0.86

Chemical Structure| 1159825-08-7

A189900 [1159825-08-7]

4-(Benzyloxy)-3-methoxyaniline hydrochloride

Similarity: 0.85

Chemical Structure| 60481-02-9

A188510 [60481-02-9]

(4-Phenoxyphenyl)hydrazine hydrochloride

Similarity: 0.82

Hydrazines

Chemical Structure| 60481-02-9

A188510 [60481-02-9]

(4-Phenoxyphenyl)hydrazine hydrochloride

Similarity: 0.82

Chemical Structure| 19501-58-7

A184414 [19501-58-7]

4-Methoxyphenylhydrazine hydrochloride

Similarity: 0.82

Chemical Structure| 39232-91-2

A236316 [39232-91-2]

3-Methoxyphenylhydrazine hydrochloride

Similarity: 0.82

Chemical Structure| 104033-62-7

A116063 [104033-62-7]

(4-Isopropoxyphenyl)hydrazine hydrochloride

Similarity: 0.81

Chemical Structure| 2011-48-5

A193694 [2011-48-5]

(4-Methoxybenzyl)hydrazine hydrochloride

Similarity: 0.70